Authors: Ravindran, Arun V¹; Bradbury, Cheryl²; McKay, Martha³; da Silva, Tricia L⁴

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 11, August 2007 , pp. 1693-1710(18)

Publisher: Informa Healthcare

Abstract:

Risperidone has been shown to be a safe and effective atypical antipsychotic agent. It was initially approved for the treatment of schizophrenia, and now, in many countries, is used to treat other conditions, including bipolar disorder, dementia and behavior problems in a range of age groups. Yet, frequent off-label use by clinicians to treat other mood and anxiety disorders and behavioral disorders is common and requires an examination of the risks and benefits in such populations. A review of the literature provides varying levels of evidence supporting its use in a range of depressive and anxiety disorders, and in special populations, including children and the elderly. Most reports are based on short-term studies and include its use both as monotherapy and as an augmenting agent to other psychotropics, and in a range of doses. Further randomized controlled trials are needed to confirm the efficacy and tolerability of risperidone, both short- and long-term, in many of these conditions. The published evidence is summarized, with recommendations and suggestions for its use.

Keywords: anxiety disorders; atypical antipsychotic; behavioral disorders; dopamine; mood disorders; risperidone; serotonin

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1517/14656566.8.11.1693

Affiliations: 1: 1Professor of Psychiatry, University of Toronto, Clinical Director, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, 250 College Street, ON M5T 1R8, Toronto, Canada +416 979 6933; +416 260 4171;, Email: arun_ravindran@c 2: 2Psychology Intern, Anxiety Disorders Clinic, Centre for Addiction and Mental Health 3: 3Research Co-ordinator, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health 4: 4Administrative Supervisor, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health

Publication date: 2007-08-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Ravindran, Arun V ;  Bradbury, Cheryl ;  McKay, Martha ;  da Silva, Tricia L

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers